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ABSTRACT
Dishevelled-3 (Dvl3) is regarded as a binding hub with many different interacting 
partners. However, its regulation and mechanism on cancer stemness remain to be 
explored. In this study, we showed that Dvl3 was significantly overexpressed in human 
hepatocellular carcinomas (HCCs) and promoted cancer stemness both in vitro and 
in vivo. We found that the non-phosphorylated (NP)-Dvl3 was more stable than the 
phosphorylated form, more active in activating β-catenin transcriptional activity, and 
more potent in enhancing self-renewal ability in HCC cells. Mechanistically, we confirmed 
that the homeodomain-interacting protein kinase-2 (HIPK2) and E3 ubiquitin ligase 
ITCH were able to physically bind to Dvl3 protein. Knockdown of HIPK2 and the protein 
phosphatase regulatory unit C-alpha (PP1Cα) resulted in sustained Dvl3 phosphorylation 
and hence decrease in the NP form of Dvl3. On the other hand, knockdown of E3 ubiquitin 
ligase ITCH reduced the phosphorylation-induced degradation and stabilized the 
phosphorylated Dvl3 protein. Furthermore, the NP-Dvl3 enhanced the LGR5 promoter 
activity to upregulate LGR5 expression, which was associated with increased cancer 
stemness in HCC. Our findings established that HIPK2/PP1Cα/ITCH axis sustains the de-
phosphorylation of Dvl3. This post-translational modification of Dvl3 in turn maintains 
LGR5 expression and enhances the cancer stemness properties in HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third 
leading cause of cancer deaths worldwide [1]. One of the 
frequently deregulated pathways in HCC is Wnt signaling. 
From our and others’ previous results, somatic mutations 
of β-catenin are much less frequent (12-40%) [2] than 
β-catenin overexpression in human HCC (50-68%) [2, 
3], suggesting that factors other than β-catenin mutation 
contribute to β-catenin activation.
Dishevelled (Dvl) protein is an important mediator 
of the Wnt/β-catenin signaling pathway. It is a family of 
three members, namely Dvl1, 2, and 3, and sharing three 
conserved domains, DIX, PDZ and DEP domains [4]. Dvl3 
has been regarded as a binding hub with many different 
interacting partners [4]. Previously, we have demonstrated 
that Prickle-1 enhanced the ubiquitination and degradation 
of Dvl3 in HCC [5]. Recent studies suggested that the non-
phosphorylated (NP) form of another Dvl family member, 
Dvl2, is more active in HEK293 cells [6] and the de-
phosphorylation of Dvl protein promotes its stabilization in 
HeLa cells and zebra fish embryos [7]. In addition, it has 
been identified in HeLa cells and zebrafish embryos that 
the homeodomain-interacting protein kinase 2 (HIPK2) and 
protein phosphatase regulatory unit C-alpha (PP1Cα) are 
regulators of Dvl protein phosphorylation [7]: With HIPK2 
bound to Dvl3, the phosphatase PP1Cα promotes the de-
phosphorylation of phosphorylated Dvl3 and maintains Dvl3 
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protein in the non-phosphorylated form. This spares the 
Dvl3 protein from the phosphorylation-induced degradation 
by itchy E3 ubiquitin ligase (ITCH) [8].
LGR5 has been identified as a marker of crypt-
locating intestinal stem cells [9, 10] and gastric stem 
cells [11]. It is a β-catenin target gene; as an intestine 
stem cell marker in the crypt of intestine [12, 13], it 
maintains tumor initiating cells in colorectal cancer and 
gastric cancer [12, 14, 15]. It can fuel the activation of 
Wnt/β-catenin signaling in the presence of R-spondin and 
Wnt ligands [16–18]. In HCC, damage-induced LGR5-
positive cells can regenerate hepatocytes and bile ducts in 
vivo [19]. A previous report from Japan has demonstrated 
overexpression of LGR5 in HCC [17] and pro-survival 
property of LGR5 in HCC cells [20]. These suggest that 
LGR5 may enhance cancer stemness properties in HCC.
In this study, we found that, in human HCCs, Dvl3 
was overexpressed at protein level as compared with the 
corresponding non-tumor livers. The NP form of Dvl3 had 
enhanced stability and activity in HCC cells in promoting 
sphere forming ability in HCC cells. Our data also suggest 
that HIPK2/PP1Cα/ITCH participates to mediate Dvl3 
phosphorylation and degradation to upregulate LGR5 
expression. This in turn promotes cancer stemness and 
HCC formation, as we demonstrated in in vitro sphere 
formation assays and in vivo tumorigenicity assays in 
immunodeficient NOD-SCID mice.
RESULTS
Dvl3 was overexpressed in human HCCs and 
its stability and activity were determined by 
its phosphorylation status in promoting sphere 
formation ability
Using Western blot analysis, we observed 
significantly higher protein expression levels of Dvl3 in 
the HCC tumors than the corresponding non-tumorous 
livers in 20 randomly selected human HCC pairs (P < 
.001) (Figure 1A and Supplementary Figure 1A). Previous 
studies have demonstrated that phosphorylation of 
another Dvl family member, Dvl2, at its C-terminal tail 
suppressed the Wnt signaling activity in HEK293 cells 
[6]. As the concerned phosphorylation sites are conserved 
among Dvl protein family members [6], we investigated 
whether the phosphorylation of Dvl3 might also suppress 
its ability to activate Wnt/β-catenin signaling in HCC 
cells. We constructed the phosphorylation-defective 
mutants of Dvl3 by mutating the reported phosphorylation 
sites at serine residues 578 and 581 to alanine residues 
(P2A) (Figure 1B). Successful mutation of the concerned 
phosphorylation sites on the Flag-tagged Dvl3 protein 
resulted in the phospho-defective mutant. In the Western 
blot, the upper band was lost as compared to the wild-
type counterpart (Supplementary Figure 1B). The upper 
band corresponds to the phosphorylated Dvl3 (P-Dvl3) 
protein as previously reported [6] and we were able to 
verify this using phosphatase treatment on the immuno-
precipitated Dvl3 protein (Supplementary Figure 1C) and 
the administration of phosphatase inhibitor okadaic acid to 
the cell culture (Supplementary Figure 1D). Furthermore, 
we observed increased stability of the P2A phospho-
defective mutant as compared to the wild-type, as shown 
upon treatment with cycloheximide (CHX) in Huh-7 
(Figure 1C). This led to the accumulation of Dvl3 P2A 
as compared with the Dvl3 wild-type protein, and such 
accumulation was observed in multiple HCC cell lines, 
including Huh-7, PLC/PRF/5, BEL-7402 and SMMC-
7721 (Supplementary Figure 1E). This phenomenon was 
irrespective of the type of protein tag used on the Dvl3 
protein (Supplementary Figure 1F). In addition to its 
increased stability, the P2A mutant was more active than 
the wild-type in activating the β-catenin transcriptional 
activity, as shown in the TOP/FOP dual luciferase reporter 
assay (P < .010) (Figure 1D). Importantly, the Dvl3 P2A 
mutant also enhanced the sphere forming ability of Huh-
7, PLC/PRF/5 and SMMC-7721 cells as compared to the 
wild-type (P = .022, P = .018, and P = .023, respectively) 
(Figure 1E and Supplementary Figure 1G). These findings 
demonstrated that the non-phosphorylated Dvl3 (NP-Dvl3) 
was more stable and active than the P-Dvl3 in HCC cells.
Dvl3 protein dephosphorylation was governed by 
HIPK2-PP1Cα-ITCH axis in HCC
We explored the possible regulatory mechanism by 
HIPK2-PP1Cα-ITCH axis on Dvl3 in HCC cells. First, 
using co-immunoprecipitation (Co-IP) assay, we found that 
HIPK2 protein was able to physically bind to Dvl3 protein 
in Huh-7 cells (Figure 2A and 2B). We then used siRNA to 
knock down HIPK2 and PP1Cα, respectively, in Huh-7 cells 
(Figure 2C and 2D). Knockdown of HIPK2 sustained the 
Wnt3a-induced phosphorylation of Dvl3 protein at higher 
levels, in terms of the P-Dvl3 to NP-Dvl3 ratio, than the NTC 
(Figure 2E). Similarly, when the phosphatase PP1Cα was 
knocked down, the Wnt3a-induced Dvl3 phosphorylation, 
in terms of the ratio of P-Dvl3 to NP-Dvl3 protein levels, 
was increased and sustained for longer duration (Figure 
2F). This indicates that HIPK2 and PP1Cα suppress Dvl3 
phosphorylation and result in the increase of NP-Dvl3.
Next, we examined whether ITCH also suppressed 
Dvl3 protein level in HCC, as suggested from the previous 
study on HEK293 cells [8]. Using Co-IP assay, we found 
that ITCH physically bound and interacted with Dvl3 
protein in Huh-7 cells (Figure 3A and 3B). Knockdown of 
ITCH sustained the Wnt3a-induced P-Dvl3 in Huh-7 cells 
and this resulted in increase in the ratio of P-Dvl3 to NP-
Dvl3 for longer duration than the NTC (Figure 3C and 3D). 
Of note, in human HCCs, the ITCH mRNA expression 
levels negatively correlated with the total Dvl3 protein (P 
= .01) (Figure 3E). The data support a role of ITCH in 
down-regulating the Dvl3 protein level in human HCCs.
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Figure 1: Dvl3 protein expression is enhanced in HCCs and the non-phosphorylated Dvl3 is the more stable and active 
form of Dvl3 in HCC cells to promote sphere formation. (A) Scatter plot showing a summary of Dvl3 protein expression in 20 
paired HCC (T) and corresponding non-tumorous tissues (NT) as analyzed by Western blot densitometry. (B) Schematic diagram showing 
mutation of serine residues 578 and 581 on N-terminal Flag-tagged Dvl3. (C) The NP-Dvl3 mutant showed sustained protein stability at 
different time points as compared to the WT upon treatment with cycloheximide (CHX) at 10 ug/ml in Huh-7. (D) The NP-Dvl3 mutant 
was more active than WT Dvl3 in Huh-7. To ensure normalization of the amount of Dvl3 protein (right) to allow comparison in TOP/FOP 
reporter assays, DNA constructs were transfected at the following amounts: 2.5 μg of Dvl3 WT, 0.875 μg and 1.0 μg of Dvl3 P2A for lanes 
1, 2, and 3, respectively. (E) The NP-Dvl3 mutant promoted greater sphere forming ability than WT Dvl3 in Huh-7. All in vitro experiments 
were carried out in at least 3 independent trials and the values are represented as mean ± SD.
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Figure 2: HIPK2/PP1Cα interacts with Dvl3 and is required for Dvl3 protein de-phosphorylation in HCC cells. (A) 
Schematic diagrams for the DNA constructs used in the Co-IP experiment. (B) Co-IP experiment showed the binding of HIPK2 and Dvl3 
proteins in Huh-7 cells. The result of one representative trial of the 3 independent experiments is shown. (C) Efficient knockdown of HIPK2 
by siRNA in Huh-7 cells as compared to NTC. (D) Efficient knockdown of PP1Cα by siRNA in Huh-7 cells as compared to NTC. (E) 
Knockdown of HIPK2 sustained Wnt3a-induced phosphorylation of Dvl3 in Huh-7 cells. The cells were treated with Wnt3a conditioned 
medium (Wnt3a CM) for the indicated time periods upon transfection of the siRNA. Western blots of both short and long exposure (exp.) 
are shown (left). Densitometry showing the ratio of the phosphorylated (P-) to the non-phosphorylated (NP-) Dvl3 (P/NP) plotted relative to 
the respective L-cell control medium (LC) upon the knockdown of HIPK2 (right). (F) Knockdown of PP1Cα sustained the Wnt3a-induced 
phosphorylation of Dvl3 in Huh-7 cells. The cells were treated with Wnt3a-conditioned medium (Wnt3a CM) for the indicated periods 
of time upon transfection of the siRNA. Western blots of both short and long exposure (exp.) are shown (left). Densitometry showing the 
ratio of the P- to the NP-Dvl3 (P/NP) plotted relative to the respective L-cell control medium (LC) upon the knockdown of PP1Cα (right).
Oncotarget39434www.impactjournals.com/oncotarget
NP-Dvl3 and HIPK2-PP1Cα axis upregulated 
LGR5 expression in HCC cells
First, knockdown of Dvl3 in Huh-7 cells suppressed 
LGR5 expression whereas transient transfection of 
Dvl3 significantly increased it (Supplementary Figure 
2A). Hence, we made use of LGR5 expression as a 
downstream readout for studying the activity of Dvl3 
protein. With luciferase reporter assay, Dvl3 P2A mutant 
resulted in greater LGR5 promoter activity (2.1 folds) 
than the wild-type Dvl3 (P = .001) (Figure 4A). In 
addition, our panel of HCC cell lines showed a trend of 
positive correlation between NP-Dvl3 to P-Dvl3 ratio and 
LGR5 mRNA expression. Those cell lines with higher 
NP-Dvl3 to P-Dvl3 ratio (e.g. PLC/PRF/5, Huh-7 and 
Hep3B) had higher LGR5 mRNA expression (Figure 4B 
and Supplementary Figures 2B to 2D). On the contrary, 
those cell lines (e.g. SMMC-7721, HepG2 and HLE) 
Figure 3: ITCH regulates Dvl3 protein expression in HCCs. (A) Schematic diagram of the DNA construct of the N-terminally 
myc-tagged ITCH. (B) Co-IP experiment showed interaction between Dvl3 and ITCH proteins in Huh-7 cells. (C) Efficient knockdown of 
ITCH in Huh-7 using siRNA as compared to the NTC (left). Knockdown of ITCH increased the level of Wnt3a-induced P-Dvl3 protein in 
Huh-7 cells (right). The cells were treated with Wnt3a-conditioned medium (Wnt3a CM) for the indicated periods of time after transfection 
of the siRNA. Western blots of both short and long exposure (exp.) are shown. The result of one representative trial of the 3 independent 
experiments is shown. (D) Densitometry showing the P- to NP-Dvl3 ratio (P/NP) and plotted relative to the respective L-cell control 
medium (LC). (E) The ITCH mRNA level inversely correlated with the Dvl3 protein level in human HCCs.
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with P-Dvl3 higher than NP-Dvl3 protein had almost 
undetectable LGR5 mRNA expression.
Furthermore, in human HCCs, the HIPK2 mRNA 
levels positively correlated with those of LGR5 (R2 = 
.262, P = .001) (Figure 4C). Besides our own data, we 
also found significant correlation between the mRNA 
levels of HIPK2 and LGR5 in HCC tumors in The Cancer 
Genome Atlas (TCGA) dataset (R2 = .427, P = .001) 
(Supplementary Figure 2E). Similar observation was also 
seen in our HCC cell line panel, the HIPK2 mRNA levels 
of which significantly correlated with those of LGR5 
(R2 = .738, P = .002 by linear regression analysis) (Figure 
Figure 4: Non-phosphorylated Dvl3 as mediated by HIPK2/PP1Cα helps sustain LGR5 mRNA expression in HCC. 
(A) Schematic diagram showing the cloning of LGR5 promoter to pGL3-Basic reporter plasmid used in the luciferase reporter assays 
(left). The NP-Dvl3 mutant had greater LGR5 promoter activity than the WT Dvl3 (right) in Huh-7 cells. (B) Summary of Dvl3 protein 
phosphorylation status and LGR5 mRNA in HCC cell line panel (left). The grey-shaded boxes represent values greater than the respective 
median among the cell lines while the white boxes indicate the opposite. Upon comparison of LGR5 expression levels between cell lines 
with NP>P Dvl3 and those with NP≤P Dvl3 (right), there was significant up-regulation of LGR5 expression in the former (P = 0.029, 
Mann Whitney test). Detailed values for individual cell lines can be found in Supplementary Figure 2D. (C) HIPK2 correlated with 
LGR5 at mRNA levels in our human HCC cohort. The fold difference of the mRNA expression between tumor and corresponding non-
tumorous livers in terms of –ddCT for LGR5 and HIPK2 was plotted against each other to show their significant correlation in HCC by 
linear regression (N=42). Linear regression analysis was performed on HIPK2 and LGR5 mRNA levels. (D) HIPK2 correlated with LGR5 
at mRNA levels in a panel of human HCC cell lines, including BEL-7402, PLC/PRF/5, SMMC-7721, Huh-7, Hep3B, HepG2, HLE and 
MHCC-97L. Linear regression analysis was performed on HIPK2 and LGR5 mRNA levels. Detailed values for individual cell lines can 
be found in Supplementary Figure 2D. (E) HIPK2 mRNA expression was significantly higher in LGR5-high cells than LGR5-low cells in 
BEL-7402. LGR5 promoter driven cyan-fluorescent protein (CFP) was used to indicate LGR5 expression and by fluorescence-activated cell 
sorting (FACS), the BEL-7402 cells with CFP signals and those without were sorted out. (F and G) Knockdown of HIPK2 by siRNA (F) 
significantly suppressed LGR5 expression in Huh-7 cells. (H) Knockdown of PP1Cα by siRNA significantly suppressed LGR5 expression 
in Huh-7 cells. All in vitro experiments were carried out in at least 3 independent trials and the values are represented as mean ± SD.
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4D). In order to investigate whether HIPK2 expression 
was specific to LGR5-high subpopulation within a cell 
line, we separated HCC cells with high LGR5 expression 
and those without by fluorescence-activated cell sorting 
(FACS). We found significantly enhanced HIPK2 
expression in the HCC cells with high LGR5 expression 
(Figure 4E and Supplementary Figures 2F and 2G). 
These data indicated a significant association between 
HIPK2 and LGR5 expression and prompted us to further 
investigate whether HIPK2 expression could affect LGR5 
expression.
We found that knockdown of HIPK2 (Figure 4F) 
significantly suppressed LGR5 expression in Huh-7 cells 
(P = .001) (Figure 4G). Correspondingly, knockdown of 
PP1Cα (Figure 2D) also significantly suppressed LGR5 
expression (P < .001) (Figure 4H). This indicates that 
HIPK2 and PP1Cα regulate Dvl3 phosphorylation and also 
upregulate LGR5 expression in HCC cells.
Dvl3, LGR5 and HIPK2 mediated stemness 
properties in HCC cells
As Dvl is an important mediator of the Wnt signaling 
pathway [21] which is implicated in cancer stem cell 
maintenance in other cancers [22–25], we examined the 
role of Dvl3 in regulating the stemness features in HCC. We 
observed that knockdown of Dvl3 significantly suppressed 
the sphere formation ability of both Huh-7 and MHCC-
97L HCC cell lines (P = .037 and .008, respectively) as 
compared to the non-target control (NTC) (Figure 5A and 
Supplementary Figure 3A). Furthermore, knockdown of 
Dvl3 significantly suppressed the expression of stemness 
genes (Supplementary Figure 3B) and enhanced the chemo-
sensitivity towards the chemodrug cisplatin as compared 
with the NTC (P = .005 and .016 for Huh-7 and MHCC-
97L, respectively) (Supplementary Figure 3C). For the effect 
of Dvl3 knockdown on in vivo tumorigenicity, 5 x 104 and 
5 x 105 cells were injected into NOD-SCID mice. Dvl3 
knockdown in Huh-7 cells reduced the incidence of tumor 
formation in vivo as compared to the NTC group (Figure 5A). 
A similar trend was observed in Dvl3-knockdown MHCC-
97L cells, and there was a reduction in the incidence of 
tumor formation with injection of 5 x 104 Dvl3-knockdown 
cells as well as a delay in tumor onset (Supplementary 
Figure 3A). It was also noted that the knockdown of Dvl3 
did not significantly suppress the exponential growth rate of 
individual tumors (Supplementary Figures 3D and 3E) as 
we monitored the sizes of individual tumors throughout the 
course of the experiment.
As we demonstrated that Dvl3 upregulated LGR5 
expression in HCC cells (Supplementary Figure 2A), 
we also investigated the role of LGR5 in HCC stemness. 
Stable knockdown of LGR5 with shLGR5 #86 suppressed 
the sphere formation ability in both Huh-7 and MHCC-
97L cells (P = .034 and P = .001, respectively) (Figure 
5B and Supplementary Figure 3F). Those cells with 
significantly higher LGR5 expression as obtained from 
FACS showed significantly enhanced sphere forming ability 
(Supplementary Figures 2F, 2G and 3G). Furthermore, 
knockdown of LGR5 suppressed the tumor formation 
incidence in NOD-SCID mice in both Huh-7 and MHCC-
97L (Figure 5B and Supplementary Figure 3G). The 
knockdown clones showed delayed tumor onset for Huh-
7 and more so for MHCC-97L when 5 x 104 and 5 x 105 
cells were injected. Lastly, in addition to the finding that 
HIPK2 promoted NP-Dvl3 to enhance LGR5 expression in 
HCC cells, we observed that functionally, HIPK2, Dvl3 and 
LGR5 promoted HCC stemness. With stable knockdown 
approach, knockdown of HIPK2 significantly suppressed 
sphere formation (Supplementary Figure 3H).
DISCUSSION
In this study, we found that Dvl3 expression was 
upregulated in human HCCs. We have shown that 
Dvl3 promoted cancer stemness in terms of enhanced 
tumorigenicity, sphere formation ability, chemoresistance, 
and expression of stemness genes. However, how its 
stability is controlled has not been previously clarified.
When Dvl3 is phosphorylated upon Wnt stimulus, 
it appears as a more slowly migrating band (P-Dvl3) 
as compared to the faster migrating band (NP-Dvl3) in 
Western blots [6, 7, 26–29], and hence P-Dvl3 was believed 
to be the active form in the past. However, this notion has 
recently been debated. First, Dvl phosphorylation occurs 
after the activation and accumulation of β-catenin [27]. 
Second, hyper-phosphorylation of Dvl by overexpressing 
CK1ε does not result in the punctate distribution of Dvl 
which is characteristic of Wnt signaling activation [6, 
26]. Third, mutating the phosphorylation sites at the 
C-terminal tail of Dvl2 enhances Wnt/β-catenin signaling 
[6]. Therefore, P-Dvl may not be the active form and its 
appearance may just represent the legacy of an already 
activated Wnt pathway. A recent study further showed 
that HIPK2 facilitates PP1Cα to de-phosphorylate Dvl1 
protein in HeLa cells and zebra fish embryo to promote the 
stabilization of the Dvl1 protein [7]. Also, the E3 ubiquitin 
ligase ITCH promotes the degradation of P-Dvl protein in 
HEK293 cells [8]. In line with these findings, our study 
found that the phospho-defective form of Dvl3 protein 
showed enhanced stability and activity on the Wnt/β-
catenin signaling in HCC cells. This indicates that this 
phosphorylation of Dvl3 is linked to the dynamics of the 
amount of Dvl3 protein.
Such dynamics may represent a built-in feedback 
regulatory mechanism of the signaling. While Wnt 
ligands activate the signaling, they may also trigger Dvl 
phosphorylation to prime part of the Dvl protein pool to 
become less active. In this way, less amount of active Dvl3 
will be available to convey further signals downstream to 
prevent prolonged activation of the pathway. This may 
allow time for degradation of the accumulated β-catenin to 
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Figure 5: Knockdown of Dvl3 and LGR5 suppresses stemness properties in HCC cells. (A) Efficient knockdown of Dvl3 
was established in Huh-7 cell line using sh#45 as compared to the non-target control (NTC). This suppressed sphere formation in vitro 
significantly and inhibited tumorigenicity in vivo. The median number of days of tumor onset was calculated based on the successfully 
formed tumors. (^ The numbers of days after the injection for the onset of the six tumors in the NTC group were 28, 46, 46, 60, 83 and 95, 
while those for the two tumors in the sh#45 group were 23 and 67.) (B) Efficient knockdown of LGR5 was established in Huh-7 cells using 
sh#86 as compared to the non-target control (NTC). This suppressed sphere formation in vitro significantly and inhibited tumorigenicity 
in vivo.
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return the pathway activity to the initial basal level in order 
to prepare the cells for subsequent round of activation. 
This appears to be critical to the concise temporal and 
spatial Wnt-mediated biological processes.
The presence of HIPK2/PP1Cα and ITCH may offer 
additional layers of regulation on Dvl3 quantity and activity 
to help modulate the Wnt signaling pathway activity: (1) 
when the P-Dvl3 resulted from Wnt stimulation is de-
phosphorylated by HIPK2, such Dvl3 protein can return 
back to the initial pool of active NP-Dvl3 to maintain 
sustainable Wnt signaling activity; (2) when the P-Dvl3 
resulted from Wnt stimulation cannot be efficiently de-
phosphorylated by the HIPK2/PP1C, this may indicate an 
already excessive Wnt stimulation and ITCH will remove 
the excessive P-Dvl3 [7, 8] in order to downsize the total 
Dvl3 protein pool to prevent chronic excessive signaling 
activity. This explains why prolonged and strong Wnt 
activation consumes the amount of Dvl3 protein in the 
cells (Supplementary Figures 4A and 4B) before newly 
synthesized Dvl3 protein can replenish the loss.
LGR5 is a β-catenin target gene as well as a 
marker of crypt-locating intestinal stem cells [9, 10] 
and gastric stem cells [11]. Furthermore, we found 
that Dvl3 knockdown suppressed LGR5 while Dvl3 
overexpression enhanced LGR5 expression in HCC 
cell lines (Supplementary Figure 2A). With these, we 
used the LGR5 expression as a read-out for studying the 
functionality of Dvl3 protein on Wnt/β-catenin signaling 
and stemness properties in HCC cells. In summary, our 
study on the Dvl3-mediated Wnt signaling pathway 
(Figure 6) has revealed that Dvl3 is overexpressed in 
human HCCs. The NP-Dvl3 is the more stable and active 
form of the protein and enhances HCC stemness. HIPK2/
PP1Cα prevents Wnt3a-induced phosphorylation of Dvl3 
and preserves the activity of Dvl3. This also spares the 
Dvl3 protein from degradation by ITCH if remaining in the 
phosphorylated state otherwise. Altogether, HIPK2/PP1Cα 
and ITCH maintain the balance of Wnt/β-catenin signaling 
activity. Disturbance to such balance (e.g. by an increase 
in HIPK2 expression) may lead to aberration of Wnt/β-
catenin signaling activity and subsequent upregulation of 
β-catenin downstream target such as LGR5 to promote the 
Dvl3-driven hepatocarcinogenesis.
Figure 6: Summary of the interplay among Dvl3, HIPK2/PP1Cα/ITCH axis and LGR5 in promoting liver cancer 
stemness.
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MATERIALS AND METHODS
Clinical samples and cell lines
All HCC specimens and their corresponding non-
tumorous liver tissues were resected from Chinese patients 
between year 1992 to 2000 at Queen Mary Hospital, Hong 
Kong. Thirteen patients were male and seven were female. 
Their ages ranged from 38 to 71 years (mean = 56.1 years). 
Sixteen (80%) of the 20 patients had chronic hepatitis B 
viral infection with positive serum hepatitis B surface 
antigen (HBsAg) status. None of these patients received 
any other therapies including chemoembolization or 
chemotherapy prior to hepatic tumor resection. Following 
surgical resection, all specimens were either snap-frozen 
immediately in liquid nitrogen and stored at -80°C, or 
fixed in buffered 10% formalin for paraffin embedding. 
The use of the clinical specimens was approved by the 
Institutional Review Board of the University of Hong 
Kong/Hospital Authority. Human HCC cell lines (Hep3B, 
HLE, Huh-7, PLC/PRF/5), human embryonic kidney cells 
HEK-293, human hepatoblastoma cell line HepG2, mouse 
L-cells and Wnt3a-producing L-cells were obtained from 
American Type Culture Collection. MHCC-97L was a 
gift from Dr. Z.Y. Tang of Fudan University, Shanghai. 
BEL7402, SMMC-7721, LO2 and MIHA were obtained 
from Shanghai Institute of Cell Biology, Chinese Academy 
of Sciences. All cell lines were maintained as described 
[30].
Plasmids, cell transfection and establishment of 
stable clones
The Dvl3-expressing construct (Dvl3/
pcDNA) was a gift from Dr M. Semenov (Harvard 
University, MA). The N-terminally Flag-tagged and 
myc-tagged Dvl3 was cloned from Dvl3/pcDNA to 
FLAG/pcDNA3.1 and 2x-myc/pcDNA3.1 plasmids 
respectively. Phospho-defective mutant of Dvl3 (P2A) 
was created using mutational primers 5’-AGCGAAGG
CAGTCGGAGCAGTGGCGCCAACCGTGCCGGCA
GCGATCGGAGG-AAGGAGAAG and 5’-CTTCTCC
TTCCTCCGATCGCTGCCGGCACGGTTGGCGCCA- 
CTGCTCCGACTGCCTTCGCT. The N-terminally GFP-
tagged HIPK2 was made by cloning HIPK2 to pEGFP-C1 
plasmid. The N-terminally FLAG-tagged HIPK2 
constructs were gifts from Dr. L. Schmitz (University of 
Giessen, Germany). The N-terminally myc-tagged ITCH 
was created by cloning ITCH to 2x-myc/pcDNA3.1. 
Super8X TOP Flash and Super8X FOP Flash constructs 
were gifts from Dr. R. Moon (University of Washington, 
Seattle, WA) for TOP/FOP reporter assays. pRL-CMV 
construct with a CMV promoter-driven renilla luciferase 
reporter was transfected as reference for normalization. 
LGR5 promoter was cloned to pGL3-Basic plasmid. Small 
interfering RNA (siRNA) targeting Dvl3 was purchased 
from Dharmacon, Inc while those targeting HIPK2, PP1Cα 
and ITCH were from Integrated DNA Technologies, 
Inc. based on sequence available from literature.[7, 
8] Transfection was done using Lipofectamine 2000 
according to the manufacturer’s instruction. Dvl3, LGR5 
and HIPK2 knockdown cells were established by lentiviral 
system using the MISSION® short hairpin RNA (shRNA) 
constructs (Sigma-Aldrich, St. Louis, Missouri) under 
selection in appropriate concentration of puromycin 
according to the manufacturer’s instruction.
RNA extraction and quantitative reverse-
transcription polymerase chain reaction  
(RT-qPCR)
TRIzol reagent (Invitrogen, Carlsbad, CA) and 
Reverse-Transcription kit (Qiagen, Venlo, Netherlands) 
were used to extract total RNA and generate complementary 
DNA respectively according to the manufacturers’ 
protocols. RT-qPCR was carried out using Taqman probes 
for Dvl3 and HPRT (Applied Biosystems, Carlsbad, CA) 
in the 7900HT Fast Real-Time PCR system (Applied 
Biosystems). SYBR green RT-qPCR was used to analyze 
gene expressions in cell lines. The list of primers is shown 
in Supplementary Table 1.
Protein preparation, co-immunoprecipitation 
(Co-IP) and western blot analyses
Lysate preparation and SDS–polyacrylamide gel 
electrophoresis for Western blotting were performed 
as described [31, 32]. Antibodies for Dvl3 (Cell 
Signaling Biotechnology, Danvers, MA and Santa Cruz 
Biotechnology, Dallas, Texas), Flag-tag (Sigma-Aldrich, 
St. Louis, MO), myc-tag (Santa-Cruz Biotechnology), GFP 
(Santa-Cruz Biotechnology), β-catenin (BD Bioscience, 
Franklin Lakes, NJ), PP1Cα (Santa Cruz Biotechnology), 
ITCH (Cell Signaling Biotechnology) and β-actin (Sigma-
Aldrich) were used. Band densitometry on Western blots 
was calculated using AlphaEaseFCTM software (Genetic 
Technologies, Miami, FL). Co-IP was performed in Huh-7 
cells at 48 hours after transfection, as previously described 
[33].
Sphere formation assay
Briefly, cells were suspended in 0.25% methyl 
cellulose in serum-free DMEM/F12 in wells pre-coated 
with 1% polyHEMA to form spheres in presence of the 
necessary supplement as described [34]. At end point, the 
numbers of spheres were counted.
Fluorescence-activated cell sorting (FACS)
The LGR5 promoter-driven cyan fluorescent protein 
(CFP)-containing construct was transfected to BEL-7402 
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cells and cell sorting was performed as described [34] 48 
hrs after the transfection.
Annexin V assay
Commercial kit (BD Biosciences, Sparks, MD) was 
used according to the manufacturer’s instruction. By using 
a FACSCalibur flow cytometer and CellQuest software 
(BD Biosciences), 10,000 events were acquired per 
sample under proper gating for PI and annexin V signals 
for analysis.
In vivo tumorigenicity assay
To examine the self-renewal ability of the injected 
cells to generate tumors in immunodeficient mice [35], 
indicated numbers of cells were injected subcutaneously to 
the flanks of different groups of male NOD-SCID mice of 
4-5 weeks of age. Latency for tumor occurrence and tumor 
incidence for different groups of mice were recorded.
Dual luciferase reporter assay
TOP/FOP reporter assays were performed [36] using 
the Dual-Luciferase® Reporter (DLR™) Assay System 
(Promega, Fitchburg, Wisconsin) to determine β-catenin 
transcriptional activity, according to the manufacturer’s 
protocol. Wnt3a L-cell conditioned medium and L-cell 
conditioned medium were collected as described [37].
Statistical analyses
Chi-squared test or Fisher’s exact test was used 
to analyze categorical data, while Student’s t or Mann–
Whitney test was used for continuous data. Tests were 
considered significant when the P-value was < 0.05.
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